While the life sciences industry in Switzerland saw an overall decline in 2022, 2023 proved to be a source of improvement. Swiss biotechs raised USD 639 million, a 17% increase from the previous year.
In Switzerland, 27% of all life science companies are biotechs, with a similar split between biotech therapeutics and diagnostics (45%) and R&D services companies (40%). Other biotech companies such as agricultural, food or industrial biotech account for 15%. The canton of Basel-City leads in the number of biotech therapeutics and diagnostics companies, followed by Zurich and Vaud. Of all cantons, Zurich hosts the most biotech R&D services, medtech, and digital health companies.
Download our report to learn more about the life science industry trends in Switzerland. We want to thank our partners: the Swiss Biotech Association, Basel Area Business & Innovation and Life Science Zurich/Innovation Zurich for their collaboration on this year’s trend analysis.